Related Experiment Video
Updated: Jun 18, 2026
09:52
Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma
Published on: January 25, 2015
Intra-arterial Chemoperfusion for Lung Cancer Brain Metastases
Thomas J Vogl1, Leon V Stein1, Hamzah Adwan1
1Clinic for Radiology and Nuclear Medicine, University Hospital Frankfurt, Goethe University, Frankfurt am Main, DEU.
Cureus
|June 17, 2026
Summary
Intra-arterial chemoperfusion (IAC) shows promise as a safe palliative treatment for lung cancer brain metastases (LCBM). Further research is needed to confirm its effectiveness in improving patient outcomes.
Area of Science:
- Oncology
- Interventional Radiology
- Neuro-oncology
Background:
- Lung cancer brain metastases (LCBM) present a significant challenge in palliative care.
- Recurrent or progressive symptomatic LCBM often require advanced treatment strategies.
Purpose of the Study:
- To evaluate the safety and efficacy of palliative intra-arterial chemoperfusion (IAC) for lung cancer brain metastases (LCBM).
- To assess treatment response and overall survival in patients with recurrent or post-therapeutic progressive symptomatic LCBM.
Main Methods:
- Retrospective single-center study including 10 patients with recurrent or post-therapeutic progressive symptomatic LCBM.
- Chemotherapy regimens included carmustine or a combination of mitomycin C, gemcitabine, and cisplatin administered via IAC.
- Radiological assessment using MRI and RECIST 1.1 criteria; overall survival calculated using Kaplan-Meier method.
Main Results:
- No major complications were reported during 37 IAC sessions.
- Radiological assessment showed progressive disease in 4/8 patients, stable disease in 3/8, and complete response in 1/8.
- The mean overall survival time was 9.7 months.
Conclusions:
- Intra-arterial chemoperfusion (IAC) appears to be a safe palliative option for patients with recurrent or progressive symptomatic lung cancer brain metastases (LCBM).
- Larger studies are warranted to definitively establish the efficacy of IAC in this patient population.
